When All Else Fails: Novel Use of Angiotensin II for Vasodilatory Shock: A Case Report
Authors:
- 1 October 2018
- journal article
- research article
- Published by Wolters Kluwer Health in A&A Practice
- Vol. 11 (7) , 175-180
Abstract
Angiotensin (AT) II is an endogenous hormone that acts on venous and arterial smooth muscle to cause vasoconstriction. Recent trials have sparked great interest in its ability to be used as a vasopressor for catecholamine-refractory hypotension. Herein, we describe the successful use of AT II in a patient with a colonic perforation with septic shock refractory to conventional treatment. After AT II initiation, there was an immediate reduction in catecholamine requirement, and the patient survived.Keywords
This publication has 13 references indexed in Scilit:
- The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literatureCritical Care, 2017
- Hydroxocobalamin for the treatment of cardiac surgery-associated vasoplegia: a case seriesCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2017
- Angiotensin II for the Treatment of Vasodilatory ShockNew England Journal of Medicine, 2017
- Vasoplegic syndrome: An update on perioperative considerationsJournal of Clinical Anesthesia, 2017
- Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot studyCritical Care, 2014
- Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational studyIntensive Care Medicine, 2012
- Review of aldosterone- and angiotensin II-induced target organ damage and preventionCardiovascular Research, 2004
- Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors*Critical Care Medicine, 2003
- History About the Discovery of the Renin-Angiotensin SystemHypertension, 2001
- Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care unitsCritical Care Medicine, 1998